Compare Las Vegas Sands Corp. (LVS) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Organon & Co. Common Stock — how do they compare? Las Vegas Sands Corp. trades at $36.76 (market cap $23.98B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Las Vegas Sands Corp. is far larger — about 6.6× Organon & Co. Common Stock's market cap, and Las Vegas Sands Corp. pays the higher dividend (3.24%). Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 73 Days and Organon & Co. Common Stock for 0 Days on average.
| LVS | OGN | |
|---|---|---|
Market Cap | $23.98B | $3.61B |
Volume | 5,962,073 | 1,808,049 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $13.81 |
52-Week Low | $35.81 | $5.70 |
Typical Hold Time | 73 Days | 0 Days |
Enterprise Value | $35.86B | $11.03B |
Dividend Yield | 3.24% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $37.04, up 2.46% today, amid a bearish technical signal. The company reported revenue of $13.02B in 2025 with a net income margin of 12.59%, and recent earnings show mixed results with a Q2 2026 miss. Analysts maintain a strong buy consensus with a $58.89 price target, indicating significant upside potential. Recent news highlights Sands China's community initiatives and operational milestones, reinforcing its market presence.
The outlook for LVS is positive based on solid fundamentals and analyst optimism, but risks include high debt levels and market volatility. Investment opportunity lies in the valuation discount relative to growth prospects, though investors should monitor earnings consistency and macroeconomic factors affecting the gaming and hospitality sector.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
